Specifications
- Purity
- ≥98%
- Appearance
- White to off-white crystalline powder
- Identity
- 1H-NMR
Properties
- Solvents
- DMSO (5mg/ml), DMF (5mg/ml)
- Melting Point
- 223-224° C
- Density
- 1.17 g/cm3 at 20° C
Available from stock
Ozagrel
- SKU
- O0141
Category: API's & Intermediates
- Synonyms
- OKY-046 , (E)-3-(4-((1H-Imidazol-1-yl)methyl)phenyl)acrylic acid
- 82571-53-7
- CAS-Number
- C13H12N2O2
- Molecular Formula
- 228.2
- Molecular Weight
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
- Shipping
- AMBIENT
- Short Term Storage
- RT
- Long Term Storage
- RT
- Handling Advice
- Protect from light and moisture.
- Use / Stability
- Stable for at least 2 years after receipt when stored at RT.
- Hazard statements
- H302
- Precautionary statements
- P280-P305+P351+P338
- GHS Symbol
- GHS07
- Signal word
- Warning
- Transportation
- Not dangerous goods
- Description
- Ozagrel, an antithrombic drug, is a potent and selective TXA Synthase (thromboxane A2 , TXAS) inhibitor. Acts as a selective inhibitor of TXAS with an IC50=11nM. The beneficial effects of TXAS inhibition by ozagrel include improved motor coordination after experimental stroke, and antihypertensive effects in spontaneously hypertensive rats.
- Smiles
- O=C(/C=C/C1=CC=C(CN2C=NC=C2)C=C1)O
- InChi Key
- SHZKQBHERIJWAO-AATRIKPKSA-N
- References
- (1) J.B. Press, et al., J. Med. Chem. 29, 816 (1986) , (2) K. Morita, et al., J. Pharmacobiodyn. 11, 519 (1988) , (3) K. Kawakatsu, et al., Int. J. Clin. Pharmacol. Ther. Toxicol. 28, 158 (1990) , (4) K. Ichikawa, et al., Pharmacol. 59, 257 (1999) , (5) O. Moussa, et al., Oncogene. 27, 55 (2008) , (6) Y. Ishitsuka, et al., J. Pharmacol. Sci. 111, 211 (2009)
Ozagrel, an antithrombic drug, is a potent and selective TXA Synthase (thromboxane A2 , TXAS) inhibitor. Acts as a selective inhibitor of TXAS with an IC50=11nM. The beneficial effects of TXAS inhibition by ozagrel include improved motor coordination after experimental stroke, and antihypertensive effects in spontaneously hypertensive rats.
Additional information
| Synonyms | OKY-046, (E)-3-(4-((1H-Imidazol-1-yl)methyl)phenyl)acrylic acid |
|---|---|
| Purity | ≥98% |
| Appearance | White to off-white crystalline powder |
| CAS-Number | 82571-53-7 |
| Molecular Formula | C13H12N2O2 |
| Molecular Weight | 228.2 |
| Identity | 1H-NMR |
| Solvents | DMSO (5mg/ml), DMF (5mg/ml) |
| Melting Point | 223-224° C |
| Density | 1.17 g/cm3 at 20° C |
| Smiles | O=C(/C=C/C1=CC=C(CN2C=NC=C2)C=C1)O |
| InChi Key | SHZKQBHERIJWAO-AATRIKPKSA-N |
| Shipping | AMBIENT |
| Short Term Storage | RT |
| Long Term Storage | RT |
| Handling Advice | Protect from light and moisture. |
| Use / Stability | Stable for at least 2 years after receipt when stored at RT. |
| Hazard statements | H302 |
| Precautionary statements | P280-P305+P351+P338 |
| GHS Symbol | GHS07 |
| Signal word | Warning |
| Transportation | Not dangerous goods |
| References | (1) J.B. Press, et al., J. Med. Chem. 29, 816 (1986), (2) K. Morita, et al., J. Pharmacobiodyn. 11, 519 (1988), (3) K. Kawakatsu, et al., Int. J. Clin. Pharmacol. Ther. Toxicol. 28, 158 (1990), (4) K. Ichikawa, et al., Pharmacol. 59, 257 (1999), (5) O. Moussa, et al., Oncogene. 27, 55 (2008), (6) Y. Ishitsuka, et al., J. Pharmacol. Sci. 111, 211 (2009) |
| Quantity | 50 mg, 100 mg, Bulk |
